← AstraZeneca overview

AstraZeneca vs UK Pound Sterling/US Dollar FX Spot Rate: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

AstraZeneca PLC (AZN.LSE)

Q3 2026
▲2▼2

AstraZeneca mixed as pipeline wins offset trial failures and tariff threats

  • Oncology pipeline momentum AstraZeneca's cancer drug portfolio advanced with Etcamah's FDA approval, Tagrisso-Orpathys and Imfinzi survival benefits, and Enhertu's first-line lung cancer data, supporting future revenue growth.

    This point highlights the key positive driver of the quarter: progress in oncology treatments that could boost future sales.

  • Strategic deals and financial reaffirmation The $600m Zegfrovy acquisition, tozorakimab's COPD success with priority review, 18% Q2 EPS growth, and reaffirmed $80bn 2030 target boosted investor confidence.

    This point captures the positive financial and strategic developments that supported sentiment during the quarter.

  • Late-stage trial failures Three late-stage trial failures erased over $5bn in potential sales, volrustomig's halted trial removed a $1.3bn earner, and camizestrant missed its primary endpoint, weighing on shares.

    This point explains the major negative driver: clinical setbacks that reduced expected future revenues.

  • Tariff and merger collapse pressures US tariffs of 10–12.5% on EU pharma exports threaten costs, and a reported near-$400bn Bristol Myers merger collapsed, briefly cutting shares 9%, adding uncertainty.

    This point highlights external pressures from trade policy and a failed merger that negatively impacted the stock.

September 2026
▲3▼1

AstraZeneca climbs on drug approvals and pipeline wins

  • FDA approves Etcamah for advanced breast cancer The FDA approved Etcamah for advanced breast cancer, expanding AstraZeneca's oncology portfolio and offering a new treatment option for patients. This approval supports future sales growth.

    New drug approval is a key positive catalyst for the stock.

  • Tozorakimab succeeds in COPD with priority review Tozorakimab succeeded in COPD trials and received priority review, potentially speeding its path to market. This respiratory win diversifies AstraZeneca's revenue beyond oncology.

    Positive clinical trial result and regulatory progress drive optimism.

  • Tagrisso-Orpathys and Imfinzi combos show survival benefits Tagrisso-Orpathys and Imfinzi combinations demonstrated survival benefits in trials, reinforcing AstraZeneca's leadership in lung cancer. Enhertu also cut progression risk in first-line lung cancer.

    Clinical data readouts support growth prospects for key drugs.

  • Camizestrant misses key SERENA-4 trial Camizestrant missed the primary endpoint in the SERENA-4 first-line breast cancer trial, closing a major growth path. This setback raises concerns about the pipeline's depth.

    Trial failure is a significant negative that offsets other positive news.

Latest
▲4

AstraZeneca bets $2bn on Summit and advances key drugs

  • AstraZeneca's $2bn Summit investment and cancer collaboration AstraZeneca is investing $2bn in Summit Therapeutics for a roughly 12% stake and teaming up to test Summit's ivonescimab with AstraZeneca's cancer drugs. This expands its oncology pipeline and could add future sales, though the cash outlay is large.

    This is the period's biggest new event, directly affecting AstraZeneca's capital and pipeline.

  • Elecoglipron enters Phase 3, triggering $50m milestone AstraZeneca's licensed obesity/diabetes pill elecoglipron moved into global Phase 3 trials, earning partner Eccogene a $50m milestone. Phase 2 showed strong weight and blood-sugar reductions, so this could become a major new product in a huge market.

    New pipeline progress in a high-growth area (obesity/diabetes) supports long-term revenue expectations.

  • US filing for ORPATHYS plus TAGRISSO in lung cancer AstraZeneca submitted a US new drug application for its ORPATHYS plus TAGRISSO combination in a hard-to-treat lung cancer. If approved, it extends the life of its top-selling Tagrisso and adds a new revenue stream.

    A regulatory milestone that could expand a key franchise and support future sales.

  • Datroway-ivonescimab trial collaboration with Daiichi and Summit AstraZeneca, Daiichi Sankyo and Summit will test Datroway with ivonescimab in breast and lung cancers, starting with a Phase 3 trial. This broadens AstraZeneca's oncology combinations and could boost its cancer portfolio, though it is early-stage.

    A new collaboration that expands AstraZeneca's oncology pipeline and combination strategy.

▲3▼1

AstraZeneca's pipeline and EU approvals advance, but Europe policy and a trial miss weigh

  • EU approvals and CHMP backing expand oncology and rare-disease labels AstraZeneca won EU approval for a first-line Enhertu combination in HER2-positive breast cancer, CHMP backing for Enhertu in early breast cancer and Klygefa in myasthenia gravis, and EU approval for Trixeo in asthma. These widen approved uses, supporting future sales and the share price.

    Multiple regulatory wins broaden commercial reach and revenue outlook.

  • NHS England reimburses Enhertu, expanding access to ~1,000 patients The NHS reversed its rejection and agreed to fund Enhertu for HER2-low metastatic breast cancer in England, making about 1,000 women a year eligible. This adds real sales in a major market, though the confidential discount limits the immediate financial boost.

    Reimbursement converts a previously blocked drug into actual revenue.

  • FDA priority reviews for efzimfotase alfa and Imfinzi combo in bladder cancer The FDA granted priority review to efzimfotase alfa for rare bone disease HPP and to Imfinzi plus enfortumab vedotin for muscle-invasive bladder cancer. Faster reviews bring potential approvals closer, adding new revenue streams and strengthening the pipeline.

    Priority review shortens timelines to approval, lifting near-term sales prospects.

  • Europe pharma warning and camizestrant first-line miss cap growth hopes AstraZeneca and peers warned Europe's drug industry is losing ground, with up to 40% of approved therapies never reaching patients, a long-term regulatory risk. Separately, the SERENA-4 trial of camizestrant missed its goal in first-line breast cancer, closing off a major market expansion.

    These are real counterweights that limit the pace of growth and add uncertainty.

▲3▼1

AstraZeneca's mixed week: lung cancer wins, breast cancer setback, $15bn China bet

  • Tagrisso's 8-year survival data reinforces top seller Tagrisso cut the risk of death by 47% at eight years in early-stage lung cancer, with 79% of treated patients alive versus 64% on placebo. This strengthens the company's biggest cancer drug and supports future sales, a clear positive for the share price.

    Tagrisso is AstraZeneca's largest product, so strong long-term data directly supports revenue and investor confidence.

  • Enhertu cuts progression risk 37% in first-line lung cancer Enhertu beat standard care in first-line HER2-mutant lung cancer, cutting the risk of progression or death by 37% and improving progression-free survival by six months. This expands a key drug into earlier treatment, adding sales potential and lifting the growth outlook.

    It opens a new first-line use for a major drug, directly increasing its addressable market and future revenue.

  • Camizestrant fails key breast cancer trial The Phase III SERENA-4 trial of camizestrant (Etcamah) missed its goal in first-line advanced breast cancer, removing a path to a much larger patient group. The drug had been expected to sell over $5bn a year, so this is a real setback to growth hopes.

    It removes a major expected revenue stream and is the main negative event of the period, weighing on the shares.

  • $15bn China investment deepens key market AstraZeneca pledged $15bn to expand manufacturing and research in China, its second-largest market at about 12% of sales. This supports long-term growth but carries geopolitical risk as US rules tighten on Chinese biotech ties, so the net effect is positive but not without a counterweight.

    It is a major capital commitment that expands a key market, directly supporting the company's long-term revenue ambition.

▲4

AstraZeneca's breast cancer and COPD wins drive growth outlook

  • FDA approves Etcamah for advanced breast cancer AstraZeneca won FDA approval for Etcamah (camizestrant) in advanced breast cancer, its 10th US approval this year. A companion diagnostic was also cleared. This adds a new revenue stream and strengthens the company's cancer portfolio, supporting future sales and the share price.

    This is a major new product approval that directly boosts AstraZeneca's growth prospects.

  • Tozorakimab succeeds in COPD, FDA priority review Phase III trials showed tozorakimab significantly reduced COPD flare-ups, and the FDA accepted its application for priority review. This could become a first-in-class treatment for a large patient group, adding a potential blockbuster and lifting long-term revenue expectations.

    Positive late-stage data and regulatory progress for a new respiratory drug expand AstraZeneca's pipeline.

  • Tagrisso-Orpathys combo extends survival in lung cancer A late-stage trial showed the Tagrisso-Orpathys combination significantly extended progression-free survival in EGFR-mutated lung cancer patients with high MET levels. This supports the company's biggest cancer drug and its $80bn sales target, reinforcing confidence in future earnings.

    This trial win strengthens a key product and supports the company's long-term growth goal.

  • Imfinzi combo shows survival benefit in small cell lung cancer Amgen's trial showed its IMDELLTRA combined with AstraZeneca's Imfinzi improved overall survival in extensive-stage small cell lung cancer versus Imfinzi alone. This could increase Imfinzi's use in this setting, adding sales for an already important drug.

    A partner's trial success can boost demand for AstraZeneca's Imfinzi, a key revenue driver.

August 2026
▼3▲1

AstraZeneca mixed in August: pipeline wins offset by merger and trial setbacks

  • Late-stage lung cancer wins and Zegfrovy acquisition AstraZeneca reported two late-stage lung cancer successes for Tagrisso-savolitinib and Enhertu, and bought global rights to Dizal's Zegfrovy for $600m. These advances support future oncology sales.

    These positive pipeline and deal developments were key drivers of sentiment during the period.

  • BMS merger reports spark 9% drop Reports of a near-$400bn merger with Bristol Myers Squibb caused a 9% share drop on overpayment and antitrust fears, especially in lung cancer. The deal remains uncertain.

    The merger speculation was a major negative event that significantly impacted the share price.

  • Volrustomig trial halted, removing $1.3bn earner The volrustomig lung cancer trial was halted, eliminating a potential $1.3bn revenue stream. This setback adds to pipeline concerns.

    The trial halt was a significant negative pipeline event that weighed on shares.

  • Competitive threats and Wainua fallout BioMarin's Alesta deal threatens Strensiq, Summit's ivonescimab beat Imfinzi in biliary tract cancer, and Wainua's failed heart trial left shares about 14% below pre-failure levels.

    These competitive and pipeline setbacks contributed to the negative pressure on the stock.

▲3▼1

AstraZeneca's pipeline wins build, but a rival's trial success and old heart-drug failure linger

  • Buys global rights to lung cancer drug Zegfrovy AstraZeneca paid $600m upfront (up to $1.5bn total) for worldwide rights to Dizal's Zegfrovy, an oral lung cancer drug already approved in the US and China. It adds a new oncology earner and supports the $80bn 2030 revenue goal, lifting future sales prospects.

    A fresh, sizable pipeline acquisition that adds revenue and reinforces the growth story.

  • Tezspire succeeds in eosinophilic esophagitis Tezspire met all goals in a Phase 3 trial in eosinophilic esophagitis, a chronic swallowing condition with few good treatments. This is a third inflammatory disease for the drug, widening its market. But it is only about 1.4% of the 2030 revenue target, so the boost is modest.

    A genuine new clinical win that expands a marketed drug, though small relative to total revenue.

  • Datroway advances into bladder cancer and more lung data AstraZeneca and Daiichi Sankyo began a Phase 3 trial of Datroway in high-risk muscle-invasive bladder cancer, and reported encouraging DESTINY-Lung04 and SAFFRON lung cancer results. These broaden its antibody-drug conjugate franchise, supporting long-term sales growth.

    New trial progress that extends the oncology pipeline and future revenue base.

  • Rival ivonescimab beats Imfinzi; Wainua failure still weighs Summit's ivonescimab showed better survival than AstraZeneca's Imfinzi in biliary tract cancer, a competitive threat to a key drug. Meanwhile full data on the failed Wainua heart trial confirmed the setback, and the shares remain about 14% below pre-failure levels.

    The main counterweights: rising competition for Imfinzi and a confirmed heart-drug failure holding the stock back.

▼2▲1

AstraZeneca's lung cancer wins outweigh a pipeline miss and fresh BMS talk

  • Two lung cancer trial wins strengthen key drugs AstraZeneca's Tagrisso-savolitinib combo and Enhertu both hit their goals in late-stage lung cancer trials, improving survival for patients with few options. These add sales potential to already big cancer medicines, supporting future revenue and the share price.

    Positive late-stage data on major cancer drugs is the main new force lifting AZN.LSE.

  • Volrustomig lung cancer trial halted AstraZeneca stopped a late-stage trial of volrustomig in lung cancer after it looked unlikely to beat existing treatment. The drug had been expected to reach about $1.3bn in sales by 2032, so this removes a future earner and is a modest drag on the stock.

    This is a new pipeline setback that partly offsets the positive trial news.

  • BMS merger talk resurfaces Reports say AstraZeneca and Bristol Myers Squibb have again discussed a mega-merger. Investors worry it would distract from AstraZeneca's strong growth and bring antitrust problems, echoing the sell-off when this story first broke. The uncertainty weighs on the shares.

    Renewed merger speculation is a new event that pressures the stock, even though the earlier deal was called off.

  • New competition and a China licensing deal BioMarin agreed to buy Alesta, whose oral drug could rival AstraZeneca's Strensiq, a $1bn-plus seller. Offsetting that, AstraZeneca paid $600m upfront for global rights to Dizal's sunvozertinib, adding a new lung cancer asset. Net effect is roughly balanced.

    These two smaller items show both a competitive threat and a pipeline addition, giving a fair picture.

July 2026
▲2▼2

AstraZeneca hit by trial failures and tariff threats, but oncology and earnings shine

  • Pipeline setbacks Three late-stage trial failures (Wainua, eplontersen, Ultomiris) erased over $5bn in potential sales and raised doubts about AstraZeneca's drug development, weighing on the shares.

    These failures were a major negative force on the stock during the period.

  • US tariffs and merger collapse New US tariffs of 10–12.5% on EU pharma exports threaten costs, and a reported near-$400bn merger with Bristol Myers fell through, briefly sending shares down 9%.

    Tariffs and the failed merger created significant uncertainty and a sharp price drop.

  • Oncology and earnings strength Oncology wins, including sonesitatug vedotin's survival goal and EU breast cancer approvals, plus Q2 EPS growth of 18% and a reaffirmed $80bn 2030 target, lifted confidence.

    These positive developments provided a strong counterweight to the setbacks.

  • Deals and analyst support Licensing deals with CSPC, Sino Biopharmaceutical, and Dizal, a Royalty Pharma deal validating cliramitug, and UBS backing helped offset negative news, though analysts remain split.

    These deals and support bolstered confidence amid mixed sentiment.

▲2▼1

AstraZeneca's BMS mega-merger collapses; earnings and pipeline deals steady the stock

  • $400bn Bristol Myers merger talks called off AstraZeneca and Bristol Myers Squibb were never in merger talks, a source said, after reports of a near-$400bn deal sent the shares down about 9%. The board reportedly walked away the day after the news broke. A huge, risky deal is now off the table, removing the overhang but also the hoped-for cost savings.

    The merger saga was the period's biggest share-price driver and its collapse is the key new event.

  • Q2 beat and $80bn 2030 target reaffirmed Second-quarter core earnings per share rose 18% to $2.63, beating the $2.48 consensus, with revenue up 5% to $15.38bn. Oncology grew 16%, led by Tagrisso, Imfinzi and Enhertu. Management kept its full-year outlook and its $80bn revenue goal for 2030, reassuring investors about growth.

    Better-than-expected profits and a confirmed long-term target underpin the investment case.

  • Royalty deal validates cliramitug heart drug Royalty Pharma paid up to $425m for a 3-4% royalty on AstraZeneca's heart drug cliramitug, which is in final-stage testing with results due in 2028. The deal puts outside money behind a potential $3-5bn seller, a vote of confidence after recent heart-drug failures.

    It shows a specialist investor values a key pipeline asset, offsetting negative pipeline news.

  • Pipeline setbacks and partner deals cut both ways Ultomiris failed a late-stage trial in a rare blood disorder, and partner Ionis faces a securities probe over the Wainua failure. Offsetting this, AstraZeneca signed precision-oncology diagnostic deals with SOPHiA GENETICS and Labcorp, and its Evinova unit won a Merck KGaA AI partnership. Analysts remain split, with Citi bullish and Deutsche Bank negative.

    It gives the fair counterweight: real pipeline losses against new partnerships and divided analyst views.

▼2

AstraZeneca's $400bn BMS merger talks spook investors, shares plunge

  • Mega-merger talks with Bristol Myers Squibb send shares down 9% AstraZeneca is in preliminary talks to merge with US rival Bristol Myers Squibb in a deal worth nearly $400 billion. Investors fear AstraZeneca is overpaying and face big antitrust hurdles, especially in lung cancer where both companies compete. Shares fell about 9% on the news.

    This is the single new event that moved AZN.LSE sharply this period and is the main driver of the stock's decline.

  • Antitrust and deal-value concerns add to the sell-off Analysts warn the combined company would face serious antitrust scrutiny, especially in non-small cell lung cancer where BMS's Opdivo and AstraZeneca's Imfinzi overlap. Neither firm has enough cash to buy the other outright, so a deal may never happen. This uncertainty keeps pressure on the share price.

    It explains why the market reacted so negatively and why the decline may persist until the deal picture clears.

▲2▼2

AstraZeneca's cancer pipeline surges while heart drug setbacks and tariffs weigh

  • Sonesitatug vedotin hits survival goal in gastric cancer AstraZeneca's experimental drug sonesitatug vedotin met its main goal of helping patients live longer in a late-stage gastric cancer trial. Analysts see peak annual sales of $3–5 billion, adding a new blockbuster cancer treatment and lifting future revenue prospects.

    This is a major new pipeline win that directly boosts AstraZeneca's growth outlook and share price.

  • EU approvals expand breast cancer franchise AstraZeneca won EU approval for Etcamah in advanced breast cancer and for Datroway as a first-line triple-negative breast cancer therapy. Enhertu plus pertuzumab also got a positive EU recommendation. These expand approved treatments, driving near-term sales and reinforcing the oncology franchise.

    Multiple new EU approvals directly increase AstraZeneca's addressable market and revenue potential.

  • Heart drug eplontersen fails Phase 3 trial Partnered heart drug eplontersen failed a late-stage trial in a heart condition, removing a potential multi-billion-dollar sales opportunity. This follows the recent Wainua failure, raising doubts about AstraZeneca's cardiovascular pipeline and weighing on the stock.

    This is a fresh pipeline setback that removes a future revenue stream and hurts investor confidence.

  • US tariffs threaten pharma exports New US tariffs of 10–12.5% on many trading partners could hit EU pharmaceutical exports, including AstraZeneca's. The EU trade deal is not yet ratified, so uncertainty remains. Tariffs would raise costs and reduce profits, pressuring the share price.

    This is a new trade risk that could directly affect AstraZeneca's US sales and margins.

▲3

AstraZeneca's Wainua failure weighs, but pipeline deals and broker support offset

  • New licensing deals boost pipeline AstraZeneca signed several licensing deals: a $200 million upfront for a COPD drug from Sino Biopharmaceutical, a $1.5 billion deal for Dizal's lung cancer drug Zegfrovy, and a genomic research pact with Helix. These add promising new medicines to its pipeline, showing it can still find growth beyond setbacks, which supports the share price.

    These deals are new and show AstraZeneca's ability to replenish its pipeline, a key positive driver.

  • Enhertu UK pricing deal near AstraZeneca and Daiichi Sankyo are close to a pricing deal with NHS England for breast cancer drug Enhertu. If finalised, it would expand access to nearly 1,000 women and generate new revenue. This follows a US-UK trade agreement that raised cost-effectiveness thresholds, making a deal more likely and boosting sales prospects.

    This is a new positive development that could unlock additional revenue for a key drug.

  • UBS backs AstraZeneca as pharma alternative to AI UBS reiterated its overweight stance on European pharma, preferring AstraZeneca among large companies. It cited improving earnings revisions, low valuations, and lighter ownership. This endorsement could attract more investors to the stock, especially as weight-loss drugs are seen as a strong near-term catalyst, supporting the share price.

    A major broker's positive view can influence investor sentiment and drive demand for the shares.

▼2▲1

AstraZeneca's heart drug Wainua fails key trial, shares plunge

  • Wainua Phase 3 trial misses primary endpoint AstraZeneca's heart drug Wainua, developed with Ionis, failed its late-stage trial in ATTR-CM, a heart condition. The drug did not reduce cardiovascular events or deaths versus placebo. This removes a potential multi-billion-dollar sales opportunity and raises doubts about AstraZeneca's research pipeline, pushing the stock down sharply.

    This is the major new negative event that caused a 9%+ share drop and directly answers why AZN is moving.

  • Credibility hit and lost revenue opportunity Analysts say the trial failure may hurt AstraZeneca's credibility beyond the lost Wainua sales, which were expected to exceed $5 billion. While the company's $80 billion sales target for 2030 is not threatened, the setback dents confidence in its pipeline and could weigh on the stock until new positive data emerges.

    Explains the broader impact on investor confidence and future revenue, which affects the share price beyond the immediate drop.

  • Kidney disease deal with CSPC worth up to $1.77B AstraZeneca signed a partnership with China's CSPC for kidney disease treatments, paying $30 million upfront and up to $1.74 billion in milestones. This adds early-stage pipeline assets and shows continued investment in future growth, which can support investor confidence and the share price over time.

    A new positive deal that diversifies the pipeline and counters some negative sentiment, relevant to AZN's long-term growth story.

Q2 2026
▲1▼1

AstraZeneca advances pipeline and China strategy amid pricing and tariff risks

  • Pipeline and China expansion AstraZeneca moved oral obesity drug elecoglipron into final testing, pledged RMB 100 billion for China through 2030, and won key approvals and deals, supporting future revenue and the share price.

    This point captures the main positive forces behind the stock during the period.

  • Pricing and tariff pressures The Trump administration is probing German drug pricing and threatening tariffs, while AstraZeneca warned it may not launch new medicines in Germany if rebate hikes proceed, adding uncertainty.

    This point highlights the main risks that could squeeze future revenue and weigh on the stock.

June 2026
▲1▼1

AstraZeneca advances pipeline and China strategy amid pricing and tariff risks

  • Pipeline and China expansion AstraZeneca moved oral obesity drug elecoglipron into final testing, pledged RMB 100 billion for China through 2030, and won key approvals and deals, supporting future revenue and the share price.

    This point captures the main positive forces behind the stock during the period.

  • Pricing and tariff pressures The Trump administration is probing German drug pricing and threatening tariffs, while AstraZeneca warned it may not launch new medicines in Germany if rebate hikes proceed, adding uncertainty.

    This point highlights the main risks that could squeeze future revenue and weigh on the stock.

▲4

AstraZeneca expands oncology and kidney pipeline with EU approvals and China deals

  • Enhertu EU tumor-agnostic approval AstraZeneca's Enhertu became the first tumor-agnostic HER2 therapy approved in the EU, opening use across many cancer types. This expands the market for an already blockbuster drug, supporting future sales and profit, which helps the share price.

    This is a new regulatory win that broadens a key drug's label and market.

  • Datroway EU recommendation for breast cancer EU regulators recommended Datroway for first-line triple-negative breast cancer, potentially the first TROP2 ADC in this setting. Approval would add another oncology sales stream, reinforcing AstraZeneca's cancer franchise and supporting the stock.

    New positive regulatory step for a partnered drug, adding to growth prospects.

  • Kidney disease deal with CSPC worth up to $1.77B AstraZeneca signed a deal with China's CSPC for kidney disease treatments, paying $30 million upfront and up to $1.74 billion in milestones. This adds early-stage pipeline assets, showing investment in future growth, which can lift investor confidence.

    New partnership expands pipeline and signals long-term growth investment.

  • China approvals and collaborations for cancer drugs ORPATHYS gained a third China approval for gastric cancer, and AstraZeneca partnered with Abbisko to test Tagrisso in a new lung cancer combination. These expand use of existing drugs and strengthen AstraZeneca's China oncology presence, supporting revenue growth.

    New approvals and trial collaborations in China add incremental revenue opportunities.

▲4▼1

AstraZeneca's pipeline and China bets advance as pricing risks build

  • Oral obesity drug elecoglipron moves to final-stage trials AstraZeneca is pushing its once-daily obesity and diabetes pill elecoglipron into Phase III trials after strong mid-stage results. If approved, it would compete in the fast-growing weight-loss market, a potential new long-term sales engine that supports the share price.

    A major pipeline advance into a huge market is a core reason investors would bid the stock up.

  • Over RMB 100 billion China investment plan through 2030 AstraZeneca said it will invest more than RMB 100 billion in China by 2030, with repeated cash injections into its Qingdao base. That signals confidence in China's long-term demand and deepens its local manufacturing and sales footprint, supporting future revenue growth.

    A huge, concrete commitment to a key growth market is a big-picture positive for future earnings.

  • Ultomiris gets FDA priority review for rare kidney disease The FDA granted priority review to Ultomiris for IgA nephropathy, a rare kidney disorder, with a decision expected in late 2026. A faster review raises the odds of an earlier U.S. approval and another sales stream for an existing drug.

    A regulatory milestone that could add a new approved use is a clear positive catalyst.

  • Datroway recommended for EU approval in breast cancer European regulators recommended Datroway, developed with Daiichi Sankyo, as a first-line treatment for an aggressive breast cancer, based on a trial showing a 5-month survival gain. EU approval would expand AstraZeneca's oncology sales and strengthen its cancer franchise.

    A positive EU regulatory opinion for a major cancer drug is a direct boost to the oncology business.

  • U.S. tariff threat and German pricing pressure The Trump administration is probing German drug pricing and threatening tariffs, while AstraZeneca warned it may not launch new medicines in Germany if proposed rebate hikes go ahead. These pricing and trade risks could squeeze future revenue and add uncertainty.

    This is the main counterweight: regulatory and pricing threats that could hurt sales and sentiment.

UK Pound Sterling/US Dollar FX Spot Rate (GBPUSD.FOREX)

Q3 2026
▲1▼1

Fed-BoE Rate Gap and UK Fiscal Worries Drive Sterling

  • Fed-BoE Rate Expectations Sterling first rose on soft US data and hawkish BoE splits, then fell as Fed hike bets grew and the Fed raised rates to 3.75–4.00%, widening the US-UK rate gap.

    This is the main force moving GBP/USD throughout the quarter.

  • UK Political and Fiscal Uncertainty UK political and fiscal worries, including 18-year-high bond yields, weighed on sterling as investors fretted about the government's finances.

    This was a key drag on the pound during the quarter.

  • UK Inflation and BoE Hike Signals UK inflation at 3.1% and BoE hike signals from officials supported sterling, though Bailey and Ramsden downplaying hikes tempered gains.

    This provided support to the pound and is new information.

  • Middle East Tensions and Bank Forecasts Middle East tensions capped sterling's gains, while major bank forecasts supported it, creating a mixed backdrop for the currency.

    These factors added to the mix of influences on GBP/USD.

September 2026
▲2▼1

Fed hike widens rate gap, but BoE hike bets support sterling

  • Fed rate hike widens US-UK rate gap The Fed raised rates to 3.75–4.00%, making dollar deposits more attractive and pressuring the pound by widening the interest rate gap between the US and UK.

    This directly explains a key force pushing GBPUSD down during the period.

  • UK inflation spike and BoE hike signals UK inflation hit 3.1%, above forecast, and the BoE signalled possible hikes with three members voting to raise rates and inflation projected above 4%, supporting sterling.

    This shows a major positive force for the pound from higher expected UK rates.

  • Major banks forecast BoE hikes Barclays, JPMorgan, Goldman Sachs, BofA and Morgan Stanley forecast BoE hikes in November and February, with markets pricing ~75% odds of a November move, boosting sterling.

    This highlights market expectations that drove demand for the pound.

  • BoE officials downplay hike bets Governor Bailey downplayed hike bets and Deputy Governor Ramsden called domestic pressures subdued, creating uncertainty that tempered sterling's gains despite energy-driven inflation.

    This provides a counterweight that limited the pound's upside.

Latest
▲2

BoE hike bets build as energy-driven inflation persists, lifting sterling

  • Bailey pushes back on hike bets, but energy inflation keeps BoE hawkish BoE Governor Bailey said the market's rate curve includes a risk premium and a hike is only one possibility, which briefly weakened the pound. But he also flagged energy-driven inflation risks, and Deputy Governor Ramsden called domestic pressures subdued. The net effect is a tug-of-war, with inflation worries keeping sterling supported.

    Explains the key BoE policy signal that sets the tone for sterling this period.

  • Banks forecast BoE hikes in November and February as energy prices stay high Goldman Sachs, Barclays, JPMorgan, BofA and Morgan Stanley now expect the BoE to raise rates in November and again in February 2027, citing energy-driven inflation. More expected UK rate hikes draw global money into sterling, pushing GBPUSD up. Markets price about a 75% chance of a November hike.

    Shows growing consensus among major banks that UK rates will rise, a key force lifting the pound.

▲3▼1

Fed hikes, BoE signals hike as UK inflation hits 3.1%

  • Fed raises rates to 3.75-4.00%, widening US-UK gap The Fed raised rates by 0.25% to 3.75-4.00%, its first hike since 2023, while the BoE held at 3.75%. Higher US rates attract global money into dollars, so the pound buys fewer dollars and GBPUSD falls.

    This is the main new force pushing GBPUSD down, as the US-UK rate gap widens in the dollar's favor.

  • UK inflation hits 3.1%, keeping BoE rate-cut hopes in check UK inflation rose to a five-month high of 3.1%, above the BoE's 2.8% forecast. This makes near-term rate cuts less likely, supporting sterling by keeping UK interest rates relatively attractive.

    Higher UK inflation reduces the chance of rate cuts, which supports the pound and pushes GBPUSD up.

  • BoE holds at 3.75% but signals possible hike as inflation seen topping 4% The BoE held rates but three members voted to hike and it projected inflation above 4% in early 2027. It also halted bond sales. This hawkish stance makes pound deposits more attractive, pushing GBPUSD up.

    The BoE's hawkish hold and inflation warning support sterling by raising expectations of future UK rate hikes.

  • Barclays and JPMorgan expect BoE hikes in November and February Barclays and JPMorgan now expect the BoE to raise rates in November and again in February 2027, citing energy-driven inflation. More expected UK rate hikes draw money into sterling, pushing GBPUSD up.

    This reinforces the positive rate-differential story for sterling, as major banks forecast further BoE tightening.

August 2026
▼2▲1

Fed and BoE rate hike bets, UK fiscal strain drive sterling

  • Fed rate hike bets strengthen the dollar Fed Chair Warsh said rate hikes may be needed to curb inflation, lifting the chance of a September hike to 57.5% from 35%. Higher US rates attract global money into dollars, so the pound buys fewer dollars and GBPUSD falls.

    This is the main new force pushing GBPUSD down this period.

  • BoE rate hike calls support sterling BoE chief economist Huw Pill said the policy rate needs to rise to 4% to stop war-driven inflation becoming persistent. Higher UK rates make pound deposits more attractive, drawing money into sterling and pushing GBPUSD up.

    This is the main new force pushing GBPUSD up this period.

  • UK fiscal worries and 18-year high bond yields UK 10-year bond yields hit 5.268%, the highest since 2008, forcing the government to plan £11bn of tax rises or spending cuts. Investors worry about UK finances, which can weaken the pound and push GBPUSD down.

    New UK-specific risk weighing on sterling.

  • UK inflation at 2.9% keeps BoE on hold for now UK inflation rose to 2.9% in July, in line with expectations, so most analysts expect the Bank of England to keep rates at 3.75% for now. No immediate rate move means little fresh direction for GBPUSD.

    Explains why the BoE has not yet acted, balancing the rate-hike talk.

▼2▲1

Fed and BoE rate hike bets, UK fiscal strain drive sterling

  • Fed rate hike bets strengthen the dollar Fed Chair Warsh said rate hikes may be needed to curb inflation, lifting the chance of a September hike to 57.5% from 35%. Higher US rates attract global money into dollars, so the pound buys fewer dollars and GBPUSD falls.

    This is the main new force pushing GBPUSD down this period.

  • BoE rate hike calls support sterling BoE chief economist Huw Pill said the policy rate needs to rise to 4% to stop war-driven inflation becoming persistent. Higher UK rates make pound deposits more attractive, drawing money into sterling and pushing GBPUSD up.

    This is the main new force pushing GBPUSD up this period.

  • UK fiscal worries and 18-year high bond yields UK 10-year bond yields hit 5.268%, the highest since 2008, forcing the government to plan £11bn of tax rises or spending cuts. Investors worry about UK finances, which can weaken the pound and push GBPUSD down.

    New UK-specific risk weighing on sterling.

  • UK inflation at 2.9% keeps BoE on hold for now UK inflation rose to 2.9% in July, in line with expectations, so most analysts expect the Bank of England to keep rates at 3.75% for now. No immediate rate move means little fresh direction for GBPUSD.

    Explains why the BoE has not yet acted, balancing the rate-hike talk.

July 2026
▲2▼1

Sterling Rises on Dollar Weakness, Then Falls on UK Political Uncertainty

  • Dollar Weakness Lifts Sterling Soft US jobs and inflation data reduced expectations of Fed rate hikes, weakening the dollar and pushing GBP/USD higher. This was the main driver of sterling's rise over the period.

    It explains the primary force behind the pound's appreciation.

  • Hawkish BoE Split and Firm UK Retail Sales Support Sterling A split Bank of England vote with some officials favoring rate hikes, combined with solid UK retail sales, provided support for the pound by suggesting higher interest rates ahead.

    It highlights domestic factors that bolstered sterling.

  • UK Political and Fiscal Uncertainty Weighs on Pound A surprise Chancellor appointment and broader political uncertainty, along with weak wage growth and cooling UK inflation, dragged the pound lower as investors worried about fiscal policy.

    It identifies key UK-specific negative factors.

  • Middle East Tensions and Fed Rate Hold Create Mixed Dollar Impact Middle East tensions revived safe-haven dollar demand, capping sterling's gains, but later the Fed's rate hold and Iran diplomacy hopes weakened the dollar, lifting GBP/USD. Bailey's pushback against hikes limited further upside.

    It captures the opposing forces that influenced the dollar and thus GBP/USD.

▲3

Bank of England's hawkish split lifts pound; Fed hold and Iran diplomacy weaken dollar

  • Bank of England holds rates but three members vote for a hike The Bank of England kept its main rate at 3.75% on July 30, but three of nine officials voted to raise it, up from two before. That hawkish split makes traders think UK rates may rise sooner, which attracts money into the pound and pushes GBPUSD up.

    This is the period's biggest new UK event and directly lifts the pound via higher expected UK rates.

  • Federal Reserve holds rates, dollar falls broadly The Fed left US rates unchanged for a fifth straight meeting on July 29, with only three of twelve officials wanting a hike. When US rate rises look less likely, the dollar loses appeal, so each pound buys more dollars and GBPUSD rises.

    A new Fed decision that weakens the dollar is a core driver of GBPUSD this period.

  • Iran diplomacy hopes and suspected yen intervention weaken the dollar Fresh hopes for Iran talks and suspected Japanese intervention to support the yen knocked the US dollar lower across many currencies. A broadly weaker dollar lifts GBPUSD, helping the pound recover from a three-week low early in the period.

    New geopolitical and currency-intervention news that weakened the dollar, supporting GBPUSD.

  • UK inflation seen above target for years, but Bailey pushes back on hikes Forecaster NIESR said UK inflation will stay above 2% until 2029, and BoE's Pill warned energy prices could feed longer-term inflation, supporting the pound. But Governor Bailey said he is not leaning toward rate hikes, a counterweight that limits GBPUSD gains.

    Shows both the new inflation-risk support for the pound and the governor's pushback that caps it.

▼3▲1

UK political and fiscal uncertainty drags pound; soft data and safe-haven dollar add pressure

  • New UK Chancellor appointment sparks fiscal worries, weakening pound John Healey became Chancellor in a surprise move, pushing UK borrowing costs to a two-month high and the pound down to $1.341. Investors worry the new government will borrow more, making the pound less attractive and pushing GBPUSD lower.

    This is a new political event that directly weakens sterling by raising fiscal uncertainty.

  • UK wage growth stays weak, reducing pressure for Bank of England rate hikes Average wages excluding bonuses rose only 3.4% year-on-year, the lowest since 2020, and private-sector wage growth was just 2.9%. With little inflation pressure from pay, the Bank of England is expected to keep rates at 3.75%, making the pound less appealing versus the dollar.

    Weak wage data lowers expectations for UK rate hikes, a key negative for GBPUSD.

  • UK inflation slows more than expected, easing pressure on Bank of England UK inflation fell to 2.6% in June, below the 2.7% forecast, the slowest in 15 months. This reduces the chance of Bank of England rate hikes, weakening the pound against the dollar as investors see less reason to hold sterling.

    Lower inflation reduces the case for higher UK rates, a direct negative for GBPUSD.

  • UK retail sales unexpectedly grow, giving pound a small lift UK retail sales rose 1.0% in June, beating forecasts of a 0.3% decline. The surprise strength in consumer spending supports the pound, showing the economy is holding up despite political uncertainty, which helps GBPUSD.

    This is a new positive data point that supports sterling and counters some negative drivers.

▲2▼2

US inflation cools, Fed hike bets fade; BoE hike bets rise, lifting pound

  • Soft US inflation data weakens the dollar US consumer and wholesale inflation slowed in June, so traders cut the chance of a July Fed rate hike to 16% from 42%. When US rate-rise bets fade, the dollar usually weakens, lifting GBPUSD because each pound buys more dollars. The pound jumped to $1.3554, its highest since mid-May.

    This is the main new force pushing GBPUSD up this period.

  • BoE rate-hike bets strengthen sterling Investors now fully price a Bank of England rate hike in September and about two quarter-point hikes by December, pushing UK two-year gilt yields to their highest since May. Higher expected UK rates make the pound more attractive to hold, supporting GBPUSD. Reduced UK political uncertainty adds to the pound's appeal.

    Rising UK rate expectations are a key new support for the pound.

  • Middle East war revives safe-haven dollar demand Iran and the US exchanged intensifying fire, Iran claimed it closed the Strait of Hormuz, and oil hit near one-month highs. In uncertain times money flows to the US dollar as a safe haven, pushing GBPUSD down. The pound dipped below $1.34 on July 13 before recovering.

    This is the main new counterweight capping the pound's gains.

  • BoE deputy says war is the only inflation problem Deputy Governor Breeden said UK inflation would already be at the 2% target without the Middle East war. That hints the Bank of England may need fewer rate hikes once the war's oil-price effect fades, trimming support for the pound. It is a modest drag on GBPUSD.

    It is a new signal that could reduce future BoE rate support for sterling.

▲3▼1

Weak US jobs data and fading Fed hike bets lift pound; Middle East tensions cap gains

  • Weak US jobs data dents Fed rate-hike bets, weakening the dollar US employers added only 57,000 jobs in June, far below the 110,000 expected. That made traders doubt the Federal Reserve will raise interest rates soon. When US rate-rise bets fade, the dollar usually weakens, which lifts GBPUSD because each pound buys more dollars.

    This is the main new force pushing GBPUSD up this period.

  • Fed hike odds fall further as jobless claims stay steady Weekly US jobless claims were steady, and the market-implied chance of a July Fed rate hike dropped to about 26%. Lower odds of higher US rates reduce the dollar's appeal, supporting GBPUSD. The pound rose to around $1.3415 as the dollar fell for a second day.

    Shows the Fed rate-hike story is fading, a key new driver for the pound.

  • Middle East tensions revive safe-haven dollar demand Attacks on ships in the Strait of Hormuz and Trump saying the Iran ceasefire is over made investors nervous. In uncertain times, money often flows to the US dollar as a safe haven, which pushes GBPUSD down. The pound dipped below $1.3350 on July 6 before recovering.

    This is the main new counterweight capping the pound's gains.

  • UK factory data improves, giving sterling a small lift An upward revision to UK factory PMI data supported the pound, helping it rise against the dollar. Stronger UK economic signals can make the pound more attractive to investors, adding to GBPUSD gains. This is a modest but new positive for sterling.

    A new UK-specific positive that adds to the pound's support.

Q2 2026
▼4

Sterling Tumbles on Hawkish Fed, UK Political Turmoil

  • Hawkish Fed Lifts Dollar The Federal Reserve turned hawkish, signalling possible rate hikes that pushed the dollar to a 13-month high. A stronger dollar makes sterling weaker by comparison, as investors seek higher-yielding US assets.

    This is a primary driver of sterling weakness, as a stronger dollar directly lowers GBPUSD.

  • BoE Holds Rates, Warns on Inflation The Bank of England kept interest rates at 3.75% and warned inflation would exceed 3.25%. This gave the pound no support, as higher rates typically attract foreign capital and boost a currency.

    The BoE's inaction and inflation warning removed a potential support for sterling, contributing to its decline.

  • UK Political Turmoil Spooks Investors Andy Burnham's by-election win, fiscal loosening fears, and Keir Starmer's resignation rattled markets. Gilt yields rose to 4.81% and GBPUSD hit a seven-month low near $1.314, as political uncertainty weighed on sterling.

    Political instability directly undermined confidence in UK assets, driving sterling to multi-month lows.

  • Goldman Sachs Flags Sterling Overvalued Goldman Sachs identified sterling as the most overvalued G10 currency, citing Brexit drag and a soft BoE as medium-term headwinds. This reinforced bearish sentiment and encouraged selling of the pound.

    A major bank's warning added to negative sentiment, pressuring sterling further.

June 2026
▼4

Sterling Tumbles on Hawkish Fed, UK Political Turmoil

  • Hawkish Fed Lifts Dollar The Federal Reserve turned hawkish, signalling possible rate hikes that pushed the dollar to a 13-month high. A stronger dollar makes sterling weaker by comparison, as investors seek higher-yielding US assets.

    This is a primary driver of sterling weakness, as a stronger dollar directly lowers GBPUSD.

  • BoE Holds Rates, Warns on Inflation The Bank of England kept interest rates at 3.75% and warned inflation would exceed 3.25%. This gave the pound no support, as higher rates typically attract foreign capital and boost a currency.

    The BoE's inaction and inflation warning removed a potential support for sterling, contributing to its decline.

  • UK Political Turmoil Spooks Investors Andy Burnham's by-election win, fiscal loosening fears, and Keir Starmer's resignation rattled markets. Gilt yields rose to 4.81% and GBPUSD hit a seven-month low near $1.314, as political uncertainty weighed on sterling.

    Political instability directly undermined confidence in UK assets, driving sterling to multi-month lows.

  • Goldman Sachs Flags Sterling Overvalued Goldman Sachs identified sterling as the most overvalued G10 currency, citing Brexit drag and a soft BoE as medium-term headwinds. This reinforced bearish sentiment and encouraged selling of the pound.

    A major bank's warning added to negative sentiment, pressuring sterling further.

▼2▲1

UK political crisis and Fed rate-hike bets push pound to seven-month low

  • Starmer resignation triggers political uncertainty Keir Starmer resigned as Prime Minister, making way for a seventh UK leader in a decade. Sterling fell near its 2026 low as investors worried about fiscal loosening under likely successor Andy Burnham. Political instability makes the pound less attractive, pushing GBPUSD down.

    This is the main new political shock this period and directly weakens sterling.

  • Fed rate-hike bets lift dollar to 13-month high Traders now expect the Federal Reserve to raise rates as soon as October, with a 50/50 chance of a second hike by year-end. The dollar hit a 13-month high, making it stronger versus the pound and pushing GBPUSD to a seven-month low of $1.314.

    This is the dominant monetary force driving the dollar side of the pair.

  • BoE eases stablecoin rules, supporting sterling demand The Bank of England scrapped a planned cap on stablecoin holdings and relaxed backing rules, allowing up to 70% of reserves in short-term government debt. This could boost sterling-backed stablecoin adoption and create fresh demand for the pound, a small counterweight to the negative drivers.

    It is a new regulatory change that could support GBP demand, offering a fair counterbalance.

▼4

Sterling falls as Fed turns hawkish and UK political risk rises

  • Fed signals possible rate hike, lifting the dollar The Federal Reserve held rates but nine of 19 officials now expect a hike by year-end, pushing the dollar to a 13-month high. A stronger dollar means it takes fewer dollars to buy one pound, so GBPUSD falls.

    This is the main new force driving the dollar side of the pair.

  • Bank of England holds rates but warns inflation will rise The BoE kept its key rate at 3.75%, with two members voting for a hike. It warned inflation will climb above 3.25% later this year due to the Iran war. No cut soon means no extra support for the pound.

    The BoE decision is a key new event for the pound side of the pair.

  • UK political turmoil and spending fears hit sterling Andy Burnham's by-election win raised fears of looser fiscal rules and higher borrowing. UK 10-year gilt yields rose to 4.81%, and the pound fell below $1.32 to a two-month low as investors worried about political uncertainty.

    This is a new political shock that directly weakens the pound.

  • Goldman Sachs says sterling is the most overvalued G10 currency Goldman warned that the pound's post-Brexit recovery has overshot, leaving it the most overvalued major currency. It cited Brexit's drag on fair value and a relatively soft Bank of England as medium-term headwinds, suggesting less room for further gains.

    This adds a new fundamental valuation headwind for the pound.

© 2026 MarketIVWhy